Investigating the mechanism of decision-making in the mitochondrial protease YME1
Ended Project Grant Awarded Last action
- Award ID
- F31NS136003
- Recipient
-
Scripps Research Institute UEI PHZJFZ32NKH4
- Awarding agency
-
National Institute of Neurological Disorders and Stroke
National Institutes of Health, Department of Health and Human Services
- Obligated
- $213,848
Award facts
- Assistance listing
- 93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders
- Completion date
- Place of performance
- California, USA
Award details come from USAspending.gov.
Description
- Abstract
- YME1 is an ATP-dependent protease located in the inner mitochondrial membrane, and plays a central role in executing the functional activities of the mitochondrial protein quality control network. Preserving homeostasis within the mitochondria is critical to maintaining cellular health and preventing a wide range of human diseases resulting from the dysfunction of the mitochondria, including neurodegenerative diseases, cardiovascular disorders, and cancer. YME1 is capable of proteolytically processing a wide variety of diverse mitochondrial substrates through regulatory mechanisms that remain largely unknown. One of the most intriguing aspects of YME1 proteolytic activity arises from its unique ability to perform molecular decision-making: YME1 can choose to perform 1) processive degradation of a target substrate, whereby IT cleaves the substrate into small peptides, or 2) site-specific cleavage through which the substrate undergoes a single cleavage event and is subsequently released by YME1. One of the most well-characterized of these site-specific cleavage functions is the cleavage of the optical atrophy 1 (OPA1) protein, which is implicated in age-related eye disease, at an internal loop by the human YME1 protein (YME1L). This cleavage event produces two isoforms of OPA1, the ratio of which is crucial to regulating mitochondrial morphology and function. However, despite much investigation into the mechanistic bases for molecular decision-making performed by YME1 proteins, the atomic drivers that distinguish between these two degradation modes remain elusive. Yeast YME1 shares high sequence conservation with human YME1L, especially at the catalytic sites, making IT an excellent molecular model for investigating this substrate processing mechanism. Interestingly, the site-specific cleavage of the yeast chaperone protein TIM10 occurs at a site that shares high sequence conservation with that of human OPA1. Thus, insights gained from studies of proteolytic processing in yeast YME1 have a strong potential to apply broadly to this mechanism in human YME1L as well as related ATP-dependent proteases. This work will focus on elucidating the mechanistic details that define how YME1 selects and distinctly processes protein substrates based on its sequence and folded state. The details of this mechanism will be investigated in two aims. The first aim will combine structural and biochemical studies to examine how structural components of YME1 perceive and respond to specific sequences within targeted substrates. The second aim will explore how YME1 switches between processing modalities based on a difference in the folding stability of the targeted substrate. These combined structure-function studies will define the molecular underpinnings that regulate two distinct functional activities of an ATP-dependent protease that are required for mitochondrial health. The outcomes of this study will provide a comprehensive model of the regulation of proteolytic processing by YME1, that will enhance our understanding of human YME1L function, and how perturbations of its function are associated with mitochondrial dysfunction and human disease.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $564 | |
| Amendment | $35,974 | |
| Amendment | $35,974 | |
| Amendment | $1,280 | |
| Amendment | $1,280 | |
| Amendment | $34,694 | |
| Amendment | $0 | |
| Amendment | $34,694 | |
| Amendment | $0 | |
| Amendment | $34,694 | |
| Amendment | $34,694 | |
| Original award | $0 |
Show all 12
Quick answers
Who received award F31NS136003?
F31NS136003 was awarded to Scripps Research Institute by National Institute of Neurological Disorders and Stroke (National Institutes of Health) on June 30, 2024.
How much is award F31NS136003 worth?
$213,848 has been obligated on F31NS136003.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award